Hello, Share Pickers. Should you hate making big decisions, share pricking is not for you. A fairly frequent armchair trader has to make them all the time. It’s not just a question of whether we should dump a share, hold or buy more. There’s the more pertinent issue of timing, either long-term or at what part of the day to hit the buy or sell button. I suspect most of us are dithery decision-makers.
Hello, Share Monkeys. It’s the weekend of the Shareprophets big mining online share show. As it costs only £2.99p for access to the best mining experts in the investing business, I would urge anyone hoping to make money from one of the most exciting branches of the golden game, to part with this nominal amount to take part. As well as being an area where you could make the most money in the shortest time, it’s also, well, a minefield and you need the best info you can get.
This was a tip of the year at a 4.6p offer. I told folks to sell at 10p+. I sold just under half mine at 10.55p and warned I’d sell more at 15p which I did. So my holding is now relatively smalla nd as such I make a couple of observations about today’s fund raise which strikes me as utterly opportunistic but the right thing to do when the shares had got well ahead of themselves.
Last night Cathal Friel gave a a video interview on behalf of Open Orphan (ORPH)where he discussed a new test for Covid antibodies, like the Roche one, that open Orphan is involved in rolloing out. The video is below. An RNS to clarify quite extraordinary numbers given by Cathal in this interview is, IMHO, needed asap.
Hello Share Trudgers. In one branch of a varied career, I’ve been a medical journalist. And that allowed me to share a few TV appearances with Professor John Oxford. He’s one of Britain’s top experts on flu viruses. John is now chair of the advisory board of Open Orphan (ORPH) the pharma which has the business sense to sponsor Tom’s excellent free podcasts. And the professor has some observations about the coronavirus outbreak.
Check out what Cathal Friel of Open Orphan (ORPH) had to say about the 24 room isolation unit his company owns in the free ShareProphets Radio podcast last week HERE. Last year the utilisation was 25%, right now it must be c100% and one can only imagine the daily rate. In light of that, an article from the WSJ is below.
Open Orphan (ORPH) was one of my tips of the year at a 4.6p offer. The shares are now 5.5p bid – the recent market sell off hitting it like nearly all other stocks. But the news today of a contract potentially worth £10 million plus really does slam home the message of how cheap the shares are.
I feel like a right tit this morning. I feel played. No, I have been played. But am I selling my shares in anger, au contraire. I am certainly not as they will march materially higher.
Well that is not something you don’t see on AIM every day. My share tip of the year at 4.6p to buy on January 1, Open Orphan (ORPH) now sees its shares, which I own some of, trading at 6.45-6.5p. But the excitement is only now starting – the company is now saying that a £5 million placing at a premium to today's share price looks set to be heavily oversubscribed. Let me explain what happens next.
At the time of the tip on January 1 the shares were 4.6p to buy. They are now 6.2p to sell. Not bad but there is a stack more to come at Open Orphan (ORPH) and I expect to be able to sell my shares at 10p+ within months. The boss, Cathal Friel, has just recorded an interview (below) with the investment whores at Proactive which is not as explicit as I am about forecasts but makes some critical points.
We tipped Open Orphan (ORPH) at a 2p offer in January when it was known as Venn Life Sciences. There has been a transformative RTO since and we told you to hang on. Today the shares are 7.9p to sell...
Search ShareProphets |
Recent Comments |